Evaluates vaccination strategies against Clade I mpox in Central Africa, indicating critical insights for deployment.
Clade I mpox continues to spread in Central Africa with no sign of abating,1 however very few doses of vaccine have been deployed. Mpox vaccination strategies using either of the licenced vaccines, MVA-BN and LC16m8, are being drawn up across 17 African countries and vaccination has begun in the Democratic Republic of Congo (DRC), Rwanda and Nigeria.2 Clinical studies during the rollout could deliver much-needed data about the effectiveness of the vaccine against clade I mpox. Choosing the right study design is fundamental.
No takes yet. Share an insight, caveat, or question.
Pley et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: